Novel fatty chain-modified glucagon-like peptide-1 conjugates with enhanced stability and prolonged in vivo activity

Biochemical Pharmacology

Volumn 86, Issue 2, 2013, Pages 297-308

  Han, Jing ^a   Huang, Xun ^b   Sun, Lidan ^a   Li, Zheng ^a   Qian, Hai ^a   Huang, Wenlong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cysteine modified; Fatty chain; Glucagon like peptide 1; Protracted antidiabetic effects

Indexed keywords

1 DODECYL 1H PYRROLE 2,5 DIONE; 1 HEXADECYL 1H PYRROLE 2,5 DIONE; 1 OCTYL 1H PYRROLE 2,5 DIONE; ANTIDIABETIC AGENT; CYSTEINE DERIVATIVE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; GLYCINE; HEMOGLOBIN A1C; LIRAGLUTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UTILIZATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEMOGLOBIN BLOOD LEVEL; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84884910260     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.05.012     Document Type: Article

References (34)

1. Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 2006;57:265-81. (Pubitemid 43261991)
2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. J Am Med Assoc 2007;298:194-206.
3. Sinclair EM, Drucker DJ. Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2005;12:146-51. (Pubitemid 40516402)
4. Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;330:1300-4. (Pubitemid 17156636)
5. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987;211:169-74. (Pubitemid 17049446)
6. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 2005;214:829-35.
7. Hupe-Sodmann K, Goke R, Goke B, Thole HH, Zimmermann B, Voigt K, et al. Endoproteolysis of glucagon-like peptide (GLP)-1(7-36) amide by ectopeptidases in RINm5F cells. Peptides 1997;18:625-32. (Pubitemid 27319773)
8. Chi Y, Zhang H, Huang W, Zhou J, Zhou Y, Qian H, et al. Microwave-assisted solid phase synthesis, PEGylation, and biological activity studies of glucagonlike peptide-1(7-36) amide. Bioorg Med Chem 2008;16:7607-14.
9. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003;52:751-9. (Pubitemid 36323583)
10. Madsen K, Knudsen LB, Agersoe H, Nielsen PF, Thøgersen H, Wilken M, et al. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. J Med Chem 2007;50:6126-32.
11. Briones M, Bajaj M. Exenatide: a GLP-1 receptor agonist as novel therapy for type 2 diabetes mellitus. Expert Opin Pharmacother 2006;7:1055-64. (Pubitemid 43949943)
12. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010;9: 267-8.
13. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992;267:7402-5.
14. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 2009;5:199-211.
15. Knudsen LB. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract 2010;64:4-11.
16. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7. (Pubitemid 36993328)
17. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
18. Son S, Chae SY, Kim CW, Choi YG, Jung SY, Lee S, et al. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acidmodified long-acting exendin-4 derivatives. J Med Chem 2009;52:6889-96.
19. Chae SY, Jin CH, Shin JH, Son S, Kim TH, Lee S, et al. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release 2010;14:2206-13.
20. Zhou J, Ni S, Zhang H, Qian H, Chi Y, Huang W, et al. Synthesis and bioactivity evaluation of dipeptidyl peptidase IV resistant glucagon-like peptide-1 analogues. Protein Peptides Lett 2010;17:1290-5.
21. Chi Y, Zhang H, Zhou J, Huang W, Ni S. Microwave-assisted solid phase synthesis of GLP-1-analogues. Lett Org Chem 2008;5:399-402.
22. Qian H, Chen W, Zhou J, Huang W, Zhang H, Jin J. Total synthesis of endothelin 1 by microwave-assisted solid phase method. Chin Chem Lett 2010;21: 388-90.
23. Stoffel M, Espinosa R, Michelle MLB, Bell GI. Human glucagon-like peptide-1 receptor gene: localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes 1993;42: 1215-8. (Pubitemid 23219942)
24. Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD, et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 2010;59: 3099-107.
25. Chen W, Zhou Y, Zhang H, Qian H, Huang W, Yang B, et al. Stability and bioactivity studies on dipeptidyl peptidase IV resistant glucogan-like peptide- 1 analogues. Protein Peptides Lett 2012;19:203-11.
26. Miranda LP, Winters KA, Gegg CV, Patel A, Aral J, Long J, et al. Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. J Med Chem 2008;51:2758-65. (Pubitemid 351620797)
27. Jin CH, Chae SY, Son S, Kim TH, Um KA, Youn YS, et al. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Control Release 2009;133: 172-7.
28. Al-Sabah S, Donnelly D. A model for receptor-peptide binding at the glucagonlike peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Br J Pharmacol 2003;140:339-46. (Pubitemid 37249194)
29. Jonassen I, Havelund S, Ribel U, Plum A, Loftager M, Hoeg-Jensen T, et al. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res 2006;23:49-55. (Pubitemid 43214660)
30. Kim TH, Jiang HH, Lee S, Youn YS, Park CW, Byun Y, et al. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. Bioconjugate Chem 2011;22:625-32.
31. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucoselowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999;48:1026-34. (Pubitemid 29226349)
32. Kim K, Kwon S, Park JH, Chung H, Jeong SY, Kwon IC. Physicochemical characterizations of self-assembled nanoparticles of glycol chitosan-deoxycholic acid conjugates. Biomacromolecules 2005;6:1154-8. (Pubitemid 40467865)
33. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004;117:77-88. (Pubitemid 38045329)
34. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases bcell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002;283:E745-52.